Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730169 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
A Phase 2 study, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 271
- Enrollment target
NCT02730169 is a Phase 2 study that has completed, run by Mereo BioPharma. The registered enrollment target is 271 participants.
The verdict
NCT02730169, a Phase 2 study, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 271 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety extension study (Protocol MBGS206). The study is planned to enroll 268 subjects.
Interventions
- DRUG Placebo
- DRUG BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2016-05-12 |
| Est. Completion | 2018-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730169
The ClinicalTrials.gov registry entry for NCT02730169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02730169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730169 about?
NCT02730169 is a clinical study titled "Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism". The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety ex...
What is the current status of trial NCT02730169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2016-05-12. Estimated completion is 2018-05-19.
What interventions are being tested in trial NCT02730169?
The interventions under investigation include: Placebo (DRUG), BGS649 (DRUG).
Who is sponsoring clinical trial NCT02730169?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.